Literature DB >> 12623315

Vancomycin-resistant enterococci: 15 years and counting.

L S Chavers1, S A Moser, W H Benjamin, S E Banks, J R Steinhauer, A M Smith, C N Johnson, E Funkhouser, L P Chavers, A M Stamm, K B Waites.   

Abstract

We review the history of vancomycin-resistant enterococci (VRE) and propose a causal model illustrating the roles of exposure to VRE reservoirs, patient characteristics, antimicrobial exposure, and prevalence of VRE in the progression from potential VRE reservoirs to active disease in hospitalized patients. Differences in VRE colonization and VRE infection are discussed with respect to hospital surveillance methodology and implications for interventions. We further document clonal transmission of VRE in a large, urban, teaching hospital and demonstrate VRE susceptibility to a wide array of antimicrobial agents. This model can guide the identification of mutable factors that are focal points for intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623315     DOI: 10.1053/jhin.2002.1375

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  22 in total

1.  Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center.

Authors:  Thomas E Dobbs; Mukesh Patel; Ken B Waites; Stephen A Moser; Alan M Stamm; Craig J Hoesley
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

2.  Enterococcus faecalis virulence regulator FsrA binding to target promoters.

Authors:  María Florencia Del Papa; Marta Perego
Journal:  J Bacteriol       Date:  2011-01-21       Impact factor: 3.490

3.  Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient.

Authors:  In Ji Song; Ji Won Seo; Young Eun Kwon; Young Ly Kim; Tae Seop Lim; Ea Wha Kang; Tae Ik Chang
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

4.  7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia.

Authors:  Magally Romero-Tabarez; Rolf Jansen; Marita Sylla; Heinrich Lünsdorf; Susanne Häussler; Dwi A Santosa; Kenneth N Timmis; Gabriella Molinari
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 5.  All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease.

Authors:  Tyler G St Denis; Tianhong Dai; Leonid Izikson; Christos Astrakas; Richard Rox Anderson; Michael R Hamblin; George P Tegos
Journal:  Virulence       Date:  2011-11-01       Impact factor: 5.882

6.  Bile-mediated aminoglycoside sensitivity in Lactobacillus species likely results from increased membrane permeability attributable to cholic acid.

Authors:  Christopher A Elkins; Lisa B Mullis
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

7.  The N-terminal domain of enterococcal surface protein, Esp, is sufficient for Esp-mediated biofilm enhancement in Enterococcus faecalis.

Authors:  Preeti M Tendolkar; Arto S Baghdayan; Nathan Shankar
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

8.  Siamycin attenuates fsr quorum sensing mediated by a gelatinase biosynthesis-activating pheromone in Enterococcus faecalis.

Authors:  Jiro Nakayama; Emi Tanaka; Reiko Kariyama; Koji Nagata; Kenzo Nishiguchi; Ritsuko Mitsuhata; Yumi Uemura; Masaru Tanokura; Hiromi Kumon; Kenji Sonomoto
Journal:  J Bacteriol       Date:  2006-10-27       Impact factor: 3.490

9.  In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models.

Authors:  William J Weiss; Timothy Murphy; Eileen Lenoy; Mairead Young
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by Etest using oxgall supplementation.

Authors:  E A Grabsch; K Chua; S Xie; J Byrne; S A Ballard; P B Ward; M L Grayson
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.